U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues

Oncology Letters

Volumn 6, Issue 4, 2013, Pages 993-999

  Hu, Jinhui ^a,b   Ye, Hongxing ^b,c   Zhang, Denghai ^a   Liu, Weiwei ^b   Li, Min ^b   Mao, Ying ^b,c   Lu, Yuan ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Glioma; IL 17; Nude mice; pEGFP N1; Tumorigenesis

Indexed keywords

CD31 ANTIGEN; COMPLEMENTARY DNA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ELISA KIT; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 84881560105     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1518     Document Type: Article

References (30)

1. Wen PY and Kesari S: Malignant gliomas. Curr Neurol Neurosci Rep 4: 218-227, 2004.
2. Couldwell WT, Dore-Duffy P, Apuzzo ML and Antel JP: Malignant glioma modulation of immune function: relative contribution of different soluble factors. J Neuroimmunol 33: 89-96, 1991.
3. Nitta T, Hishii M, Sato K and Okumura K: Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649: 122-128, 1994.
4. Roussel E, Gingras MC, Grimm EA, Bruner JM and Moser RP: Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 105: 344-352, 1996.
5. Bogdan C and Nathan C: Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann NY Acad Sci 685: 713-739, 1993.
6. Roszman T, Elliott L and Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12: 370-374, 1991.
7. Andaloussi AE, Han Y and Lesniak MS: Progression of intracranial glioma disrupts thymic homeostasis and induces T-cell apoptosis in vivo. Cancer Immunol Immunother 57: 1807-1816, 2008.
8. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, SunW, Qiao W et al: Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res14: 5166-5172, 2008.
9. Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L and Skaggs C: Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status. JNeurosurg 54: 331-337, 1981.
10. Brooks WH, Netsky MG, Normansell DE and Horwitz DA: Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med 136: 1631-1647, 1972.
11. Brooks WH, Roszman TL and Rogers AS: Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors. Cancer 37: 1869-1873, 1976.
12. Elliott LH, Brooks WH and Roszman TL: Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. J Immunol 132: 1208-1215, 1984.
13. Roszman TL, Brooks WH, Steele C and Elliott LH: Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. J Immunol 134: 1545-1550, 1985.
14. Ashkenazi E, Deutsch M, Tirosh R, Weinreb A, Tsukerman A and Brodie C: A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation. Neuroimmunomodulation 4: 49-56, 1997.
15. Watters JJ, Schartner JM and Badie B: Microglia function in brain tumors. J Neurosci Res 81: 447-455, 2005.
16. Bettelli E, Korn T and Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19: 652-657, 2007.
17. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM and Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132, 2005.
18. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA etal: Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923, 2008.
19. Toh ML, Kawashima M, Zrioual S, Hot A, Miossec P and Miossec P: IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation. Cytokine 48: 226-230, 2009.
20. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457-1464, 2009.
21. Hu J, Mao Y, Li M and Lu Y: The profile of Th17 subset in glioma. Int Immunopharmacol 11: 1173-1179, 2011.
22. Wainwright DA, Sengupta S, Han Y, Ulasov IV and Lesniak MS: The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS One 5: e15390, 2010.
23. Cantini G, Pisati F, Mastropietro A, Frattini V, Iwakura Y, Finocchiaro G and Pellegatta S: A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment. Cancer Immunol Immunother 60: 1739-1750, 2011.
24. Numasaki M, Watanabe M, Suzuki T, Takahashi H, NakamuraA, McAllister F, et al: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. JImmunol 175: 6177-6189, 2005.
25. Wakita D, Sumida K, Iwakura Y, Nishikawa H, OhkuriT, ChamotoK, et al: Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis. Eur J Immunol 40: 1927-1937, 2010.
26. Moran EM, Connolly M, Gao W, McCormick J, Fearon U and Veale DJ: Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. Arthritis Rheum 63: 3263-3273, 2011.
27. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 407: 348-354, 2011.
28. Saito Y, Oba N, Nishinakagawa S, Mizuguchi Y, Kojima T, Nomura K and Nakatsura T: Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis. Oncol Rep 23: 1325-1330, 2010.
29. Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114: 237-267, 2012.
30. Murugaiyan G and Saha B: Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175, 2009.